 |
|
Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
Kyung Hoon Cho, Young Joon Hong
Korean J Intern Med. 2020;35(5):1045-1058. Published online 2020 Aug 28 DOI: https://doi.org/10.3904/kjim.2020.140
|
|
Citations to this article as recorded by
 Coronary atherosclerotic plaque regression strategies
Anastasia V. Poznyak, Alexey Aleksandrovich Yakovlev, Mikhail А. Popov, Alexander D. Zhuravlev, Vasily N. Sukhorukov, Alexander N. Orekhov
The Journal of Biomedical Research.2024; 38: 1. CrossRef PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study
Zhi-Ming Wu, Jing Kan, Fei Ye, Wei You, Xiang-Qi Wu, Nai-Liang Tian, Song Lin, Zhen Ge, Zhi-Zhong Liu, Xiao- Bo Li, Xiao-Fei Gao, Jing Chen, Yan Wang, Shang-Yu Wen, Ping Xie, Hong-Liang Cong, Li-Jun Liu, He-Song Zeng, Lei Zhou, Fan Liu, Yong-Hong Zheng, R
American Heart Journal.2024;[Epub] CrossRef Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results
Andrea L. Vavere, Marvin Sinsakul, Emily L. Ongstad, Ye Yang, Vijayalakshmi Varma, Christopher Jones, Joanne Goodman, Vincent F. S. Dubois, Angelica L. Quartino, Sotirios K. Karathanasis, Liron Abuhatzira, Anna Collén, Charalambos Antoniades, Michael J. K
Journal of the American Heart Association.2023;[Epub] CrossRef Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review
Ahmad M Rabih, Ahmad Niaj, Aishwarya Raman, Manish Uprety, Maria Jose Calero, Maria Resah B Villanueva, Narges Joshaghani, Nicole Villa, Omar Badla, Raman Goit, Samia E Saddik, Sarah N Dawood, Lubna Mohammed
Cureus.2023;[Epub] CrossRef Aging of the Arterial System
Roberto Castelli, Antonio Gidaro, Gavino Casu, Pierluigi Merella, Nicia I. Profili, Mattia Donadoni, Margherita Maioli, Alessandro P. Delitala
International Journal of Molecular Sciences.2023; 24(8): 6910. CrossRef PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs
Nikolay Kuzmich, Elena Andresyuk, Yuri Porozov, Vadim Tarasov, Mikhail Samsonov, Nina Preferanskaya, Valery Veselov, Renad Alyautdin
Molecules.2022; 27(2): 434. CrossRef Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis
Anastasia V. Poznyak, Vasily N. Sukhorukov, Alexander Zhuravlev, Nikolay A. Orekhov, Vladislav Kalmykov, Alexander N. Orekhov
International Journal of Molecular Sciences.2022; 23(3): 1153. CrossRef The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
Riya R Parikh, Frank Breve, Peter Magnusson, Payam Behzadi, Joseph Pergolizzi
Cureus.2022;[Epub] CrossRef
|